Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027

Recursion Pharmaceuticals aims to reach $100M in partnership inflows by end of 2026, extending its cash runway through Q4 2027. CEO Christopher C. Gibson highlighted the integration of Exscientia's technology into Recursion OS 2.0, emphasizing the company's end-to-end platform capabilities from target discovery to clinical trial simulation.

Recursion Pharmaceuticals (RXRX), a leading clinical-stage TechBio company, is poised to achieve significant milestones in its financial and operational performance. According to the latest financial results for the second quarter of 2025, the company aims to reach $100 million in partnership inflows by the end of 2026, extending its cash runway through the fourth quarter of 2027. This ambitious goal underscores the company's strategic focus on leveraging its advanced platform capabilities to drive innovation and growth.

CEO Christopher C. Gibson highlighted the integration of Exscientia's technology into Recursion OS 2.0, emphasizing the company's end-to-end platform capabilities from target discovery to clinical trial simulation. This integration has enabled Recursion to accelerate its discovery and development processes, leading to tangible momentum across its pipeline.

The company reported a cash position of $533.8 million as of June 30, 2025, compared to $603.0 million as of December 31, 2024. This reduction in cash position was primarily driven by increased research and development expenses, which reached $128.6 million for the second quarter of 2025 compared to $73.9 million for the same period in 2024. The increase was primarily due to the company's agreement with Tempus and its business combination with Exscientia in November 2024.

Recursion's total revenue for the second quarter of 2025 was $19.2 million, compared to $14.4 million for the same period in 2024. This revenue was primarily driven by collaboration agreements, reflecting the company's strong partnerships with major pharmaceutical companies such as Sanofi, Roche, and Bayer.

The company's pipeline includes several promising programs, such as REC-1245 (RBM39) and REC-617 (CDK7), which are advancing towards potential development candidate designation. Additionally, Recursion's partnership with Sanofi has resulted in the achievement of a $7 million milestone payment for an immunology program, with several other programs advancing towards significant discovery milestones.

Recursion's platform, Recursion OS 2.0, continues to drive program development across biology, chemistry, and clinical development. The company has also released the Boltz-2 open-source model, which has been downloaded by over 40,000 unique users to date. This model has the potential to commoditize state-of-the-art performance for binding affinity prediction while being over 1,000 times faster and less computationally expensive than traditional methods.

In conclusion, Recursion Pharmaceuticals is well-positioned to achieve its financial and operational goals through its strategic focus on leveraging advanced platform capabilities and strong partnerships. The company's ability to extend its cash runway through the fourth quarter of 2027, combined with its ambitious targets for partnership inflows, reflects its commitment to innovation and growth in the biotechnology sector.

References:
[1] https://ir.recursion.com/news-releases/news-release-details/recursion-reports-second-quarter-2025-financial-results-and